Therapeutic strategies such as dual inhibition with trastuzumab and pertuzumab or second-line therapy with the antibody-drug conjugate trastuzumab emtansine reported negative results [8,9] (Table 1), which are incongruous to the benefit seen with these approaches in HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.